Literature DB >> 9576422

Statin trials and goals of cholesterol-lowering therapy.

S M Grundy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9576422     DOI： 10.1161/01.cir.97.15.1436

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  28 in total

Review 1.  Goals of statin therapy: three viewpoints.

Authors:  Gilbert R Thompson; Christopher J Packard; Neil J Stone
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 2.  Fibrates and high-dose statins to prevent coronary heart disease events.

Authors:  P H Jones
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

Review 3.  Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?

Authors:  P H Jones
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

4.  3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase.

Authors:  H J Park; J B Galper
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.

Authors:  Pedro J Tárraga-López; Angel Celada-Rodríguez; Miguel Cerdán-Oliver; Juan Solera-Albero; José M Ocaña-López; Mateo A López-Cara; Jaime De Miguel-Clave
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

7.  Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.

Authors:  Amar Bahadur Singh; Bin Dong; Fredric B Kraemer; Yanyong Xu; Yanqiao Zhang; Jingwen Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 8.  Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

Authors:  Peter Alagona
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

Review 9.  Who should receive HMG CoA reductase inhibitors?

Authors:  Koon K Teo; Jeffrey R Burton
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

Authors:  Esther M M Ooi; Gerald F Watts; Paul J Nestel; Dmitri Sviridov; Anh Hoang; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.